Novel dual controlled release cilostazol tablets as a patient-centric delivery system: in vitro and in vivo bioavailability in dogs and human volunteers

• In: Posters: Formulation Design and Pharmaceutical Technology
• At: Bangkok (Thailand) (2014)
• Type: Poster
• Poster code: POS-FDP039
• By: LEE, Beom-Jin (Ajou University, College of Pharmacy, Suwon, South-Korea)
• Co-author(s): Cho, Sang-Min (Ajou University, Suwon, South-Korea)
  Choi, Yun-Woong (Korea United Pharm, Seoul, South-Korea)
  Park, Chulhun (Ajou University, Suwon, South-Korea)
  Kang, Taehee (Ajou University, Suwon, South-Korea)
  
• Abstract:

  Cilostazol has been used as an antiplatelet vasodilator agent twice a day. However, it has some pharmaceutical limitations due to its low water solubility, large fluctuation of blood-concentration and unwanted side-effects such as headache, pyknocardia and heavy-headed symptoms. To overcome these pharmaceutical issues, novel dual controlled..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login